Swedencare (OM:SECARE) Stock Faces Rich P/E As Net Margin Stays Around 3%

Swedencare (OM:SECARE) has just posted its Q2 2026 numbers, with revenue of SEK672.4 million, basic EPS of SEK0.15 and trailing twelve month EPS of SEK0.49 set against year-on-year earnings growth of 23.6%. The company has seen quarterly revenue move between SEK648.8 million and SEK715.5 million over the past five quarters, while quarterly EPS ranged from a loss of SEK0.04 per share to SEK0.15 per share, placing the latest report in the context of recovering profitability and tighter net margins.

See our full analysis for Swedencare.

With the headline figures on the table, the next step is to line these earnings up against the prevailing Swedencare narratives to see which stories the numbers support and which ones they start to challenge.

See what the community is saying about Swedencare

Margins steady at 2.9% on trailing basis

• On the trailing twelve month view, Swedencare reports a 2.9% net profit margin, compared with 2.5% a year earlier, alongside net income of SEK80.1 million on SEK2.7b of revenue.
• What stands out for the bullish narrative is that this margin level sits alongside trailing earnings growth of 23.6% and forecast earnings growth of 43.1% per year, which:
  • Supports the view that Swedencare is already converting part of its revenue base into profit, even after a reported one off loss of SEK71.6 million in the last 12 months.
  • Creates a gap between today’s 2.9% net margin and the bullish expectation that margins could move well above this level over time, so future reports will be important to see if that gap actually narrows.

Revenue trends versus Swedish market

• The data points to revenue forecasts of 9.3% per year for Swedencare, compared with an expected 1.5% annual decline for the Swedish market, and trailing twelve month revenue at about SEK2.7b.
• Bullish investors often point to Swedencare’s product and channel expansion as a reason this 9.3% forecast looks achievable, and the numbers here:
  • Show revenue over the last six reported quarters moving within a fairly tight band of SEK645.5 million to SEK715.5 million, which is consistent with an established base that analysts can model against.
  • Mean that if actual growth tracks the 9.3% annual forecast while the broader Swedish market contracts, Swedencare could stand out as a higher growth option within its home market exposure.

Bulls argue that if Swedencare can keep revenue growth around these forecast levels while lifting margins, the long term narrative could look very different to what trailing margins suggest today, so it can be useful to read the more optimistic case in full through the 🐂 Swedencare Bull Case

Valuation gap, P/E and DCF fair value

• At a share price of SEK22.25, Swedencare trades on a P/E of 44.4x, which is close to the peer average of 44.6x but higher than the wider European Pharmaceuticals industry on 21.3x, and sits well below the DCF fair value of SEK96.15 referenced in the data.
• Supporters of the bullish view see the large gap between the current price and the SEK96.15 DCF fair value as a key part of the story, and the figures here:
  • Indicate the stock is priced in line with faster growing peers on a P/E basis, so the higher multiple versus the broader industry is paired with growth forecasts that are also ahead of the Swedish market.
  • Show that any move toward the DCF fair value would come from a level that is around a quarter of that estimate, which is why the combination of 43.1% forecast earnings growth and the existing P/E multiple is central to how investors frame potential valuation upside.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Swedencare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of optimism and caution around Swedencare still feels finely balanced, move quickly, review the full data set, and weigh both sides with 3 key rewards and 1 important warning sign

See What Else Is Out There

Swedencare's trailing net margin of 2.9% and relatively high 44.4x P/E compared with the wider European Pharmaceuticals industry highlight pressure on profitability and value.

If you are concerned about paying up for limited earnings efficiency right now, compare this setup with companies screened in the 239 high quality undervalued stocks to quickly spot stocks where the price looks better aligned with fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com